Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

12 August 2024

Alphamab Oncology to Present the Latest Clinical Data of Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024 Onsite Poster display date: Saturday, 14 September 2024
06 June 2024

Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products Alphamab and ArriVent will collaborate to use Alphamab's proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel ADCs
03 June 2024

Alphamab Oncology Presented Chinese Clinical Data of Anti-HER2 Bispecific ADC JSKN003 for the First Time at the 2024 ASCO Annual Meeting JSKN003 exhibited a favorable tolerability and manageable safety profile in heavily pretreated patients with advanced/metastatic solid tumors and demonstrated encouraging antitumor activity during dos...
22 May 2024

Alphamab Oncology Announces the First Patient Dosed in a Phase I Clinical Study of HER3/TROP2 Bispecific ADC Drug JSKN016 an open-label, multi-center, first-in-human (FIH) phase I clinical trial of JSKN016
06 May 2024

Alphamab Oncology to Present Chinese Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors for the First Time at the 2024 ASCO Annual Meeting Session Date and Time: 6/1/2024 9:00 AM-12:00 PM CDT
10 April 2024

Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR JSKN003 demonstrated encouraging preliminary antitumor activity in heavily pretreated patients with advanced/metastatic solid tumors
29 March 2024

Alphamab Oncology Reports Full Year 2023 Financial Results and Business Highlights Alphamab Oncology continued to focus on addressing clinical needs and adhere to differentiated innovation
26 March 2024

Alphamab Oncology Announces the First Patient Dosed in Australia in the Clinical Study of Subcutaneous Formulation JSKN033 the nature of subcutaneous injectable will lead to improved safety and convenience
22 March 2024

The Results of Phase II Clinical Study of KN046 Plus Chemotherapy as First-line Treatment for Metastatic NSCLC were Published in Cell Reports Medicine this phase II study could be a promising treatment option for this patient population
14 March 2024

Alphamab Oncology to Present Clinical Data of JSKN003 for the Treatment of HER2-expressing Solid Tumors at AACR 2024 Clinical data from the dose-escalation stage (phase Ia) of this study will be presented at this AACR conference